8-K: Iterum Therapeutics Receives Nasdaq Delisting Warning

Iterum Therapeutics plc has received a notice from Nasdaq indicating non-compliance with the minimum $1.00 bid price rule, initiating a 180-day period to regain compliance.

Summary

• Iterum Therapeutics plc received a notice from The Nasdaq Stock Market, LLC on August 25, 2025, for non-compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.
• The company's ordinary shares have traded below $1.00 for the last 30 consecutive business days.
• This notice does not result in the immediate delisting of the company's ordinary shares.
• Iterum Therapeutics has a period of 180 calendar days, until February 23, 2026, to regain compliance with the Bid Price Rule.
• To regain compliance, the closing bid price of the company's ordinary shares must be at least $1.00 for a minimum of 10 consecutive business days.
• The company may be eligible for an additional 180-day compliance period if it meets other listing requirements and provides written notice of its intention to cure the deficiency, potentially by effecting a reverse share split.

Sentiment

Score: 3

Explanation: The filing indicates a significant compliance issue with Nasdaq, carrying a material risk of delisting. While a compliance period is granted, the explicit lack of assurance regarding regaining compliance or successful appeal creates substantial uncertainty and negative sentiment for investors.

Positives

• The notice does not result in immediate delisting, providing a 180-day compliance period until February 23, 2026.
• The company has a clear path to regain compliance by maintaining a $1.00 bid price for 10 consecutive business days.
• There is a possibility of an additional 180-day compliance period if the company meets other listing standards and intends to cure the deficiency.

Negatives

• The company is not in compliance with Nasdaq's minimum bid price rule, having traded below $1.00 for 30 consecutive business days.
• There is a risk of delisting from The Nasdaq Capital Market if compliance is not regained within the specified periods.
• No assurance is provided that the company will be able to regain compliance, secure an additional compliance period, maintain other Nasdaq listing requirements, or successfully appeal any delisting determination.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price rule within the initial 180-day period, ending February 23, 2026.
• Inability to qualify for or secure an additional 180-day compliance period.
• Failure to maintain compliance with other Nasdaq listing requirements.
• Unsuccessful appeal of any delisting determination to a Nasdaq hearings panel.
• Potential negative impact on investor confidence, share liquidity, and the company's ability to raise capital due to the risk of delisting.

Future Outlook

Iterum Therapeutics plc intends to actively monitor its ordinary share closing bid price and will consider all available options to resolve the deficiency and regain compliance with the Bid Price Rule. However, there is no assurance of successfully regaining compliance, securing an additional compliance period, or winning a delisting appeal.

Management Comments

• "The Company intends to actively monitor the closing bid price of its ordinary shares and, as appropriate, will consider all available options to resolve the deficiency and regain compliance with the Bid Price Rule."
• "However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Rule during the 180-day compliance period, secure an additional 180-day compliance period, maintain compliance with the other Nasdaq listing requirements or be successful in appealing any delisting determination."

Industry Context

Non-compliance with minimum bid price rules is a common challenge for smaller-cap biotechnology and pharmaceutical companies, particularly those in clinical development stages or with limited commercial products, as their stock prices can be highly volatile and susceptible to market sentiment and funding news. Such notices often highlight underlying financial or operational challenges that have impacted investor confidence.

Stakeholder Impact

• Shareholders: Face increased risk of delisting, which could lead to reduced liquidity, potential transfer to over-the-counter markets, and a negative impact on share price and investment value.
• Investors: May perceive increased risk and uncertainty regarding the company's future listing status, potentially impacting investment decisions and the company's ability to attract new capital.

Next Steps

• Iterum Therapeutics plc will actively monitor the closing bid price of its ordinary shares.
• The company will consider all available options to resolve the bid price deficiency and regain compliance.
• If compliance is not regained within the initial period, the company may seek an additional 180-day compliance period, potentially by effecting a reverse share split.
• In the event of a delisting determination, the company may appeal the decision to a Nasdaq hearings panel.

Key Dates

Recommendation

The receipt of a Nasdaq delisting notice for failing to meet the minimum bid price rule introduces significant uncertainty and risk for Iterum Therapeutics. While a compliance period is provided, the explicit lack of assurance regarding the company's ability to regain compliance or successfully appeal a delisting decision suggests a material downside risk. Delisting would severely impact liquidity and investor confidence. Therefore, a 'sell' recommendation is prudent to mitigate exposure to this heightened risk.

Keywords

Nasdaq Delisting, Iterum Therapeutics, ITRM, Bid Price Rule, Compliance Notice, Minimum Bid Price, Reverse Share Split, Nasdaq Capital Market